Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 2.89
REGN's Cash to Debt is ranked lower than
68% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 50.45 vs. REGN: 2.89 )
Ranked among companies with meaningful Cash to Debt only.
REGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.58  Med: 1.95 Max: No Debt
Current: 2.89
Equity to Asset 0.66
REGN's Equity to Asset is ranked lower than
52% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. REGN: 0.66 )
Ranked among companies with meaningful Equity to Asset only.
REGN' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.55 Max: 0.93
Current: 0.66
0.18
0.93
Interest Coverage 139.78
REGN's Interest Coverage is ranked lower than
71% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. REGN: 139.78 )
Ranked among companies with meaningful Interest Coverage only.
REGN' s Interest Coverage Range Over the Past 10 Years
Min: 10.1  Med: 19.03 Max: 139.78
Current: 139.78
10.1
139.78
F-Score: 6
Z-Score: 14.31
M-Score: -2.70
WACC vs ROIC
12.03%
23.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 26.77
REGN's Operating margin (%) is ranked higher than
90% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. REGN: 26.77 )
Ranked among companies with meaningful Operating margin (%) only.
REGN' s Operating margin (%) Range Over the Past 10 Years
Min: -169.68  Med: -20.39 Max: 35.3
Current: 26.77
-169.68
35.3
Net-margin (%) 15.65
REGN's Net-margin (%) is ranked higher than
86% of the 748 Companies
in the Global Biotechnology industry.

( Industry Median: -80.71 vs. REGN: 15.65 )
Ranked among companies with meaningful Net-margin (%) only.
REGN' s Net-margin (%) Range Over the Past 10 Years
Min: -161.3  Med: -20.32 Max: 54.43
Current: 15.65
-161.3
54.43
ROE (%) 20.06
REGN's ROE (%) is ranked higher than
93% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. REGN: 20.06 )
Ranked among companies with meaningful ROE (%) only.
REGN' s ROE (%) Range Over the Past 10 Years
Min: -61.9  Med: -17.27 Max: 86.68
Current: 20.06
-61.9
86.68
ROA (%) 13.26
REGN's ROA (%) is ranked higher than
93% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. REGN: 13.26 )
Ranked among companies with meaningful ROA (%) only.
REGN' s ROA (%) Range Over the Past 10 Years
Min: -20.29  Med: -9.4 Max: 44.08
Current: 13.26
-20.29
44.08
ROC (Joel Greenblatt) (%) 45.86
REGN's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: -382.66 vs. REGN: 45.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
REGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -191.59  Med: -33.04 Max: 61.97
Current: 45.86
-191.59
61.97
Revenue Growth (3Y)(%) 43.90
REGN's Revenue Growth (3Y)(%) is ranked higher than
87% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. REGN: 43.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
REGN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -25  Med: 33.3 Max: 81.1
Current: 43.9
-25
81.1
EBITDA Growth (3Y)(%) 38.40
REGN's EBITDA Growth (3Y)(%) is ranked higher than
86% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. REGN: 38.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
REGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.4  Med: 29.85 Max: 83.5
Current: 38.4
-24.4
83.5
EPS Growth (3Y)(%) -6.50
REGN's EPS Growth (3Y)(%) is ranked lower than
53% of the 502 Companies
in the Global Biotechnology industry.

( Industry Median: -4.10 vs. REGN: -6.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
REGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.8  Med: -6.15 Max: 86.3
Current: -6.5
-21.8
86.3
» REGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

REGN Guru Trades in Q3 2015

Paul Tudor Jones 1,090 sh (+172.50%)
Ray Dalio 1,800 sh (+125.00%)
Mario Gabelli 2,145 sh (unchged)
Kyle Bass Sold Out
Ron Baron 7,463 sh (-0.21%)
Frank Sands 4,138,184 sh (-1.91%)
Ken Fisher 504 sh (-10.80%)
Vanguard Health Care Fund 2,447,894 sh (-11.45%)
» More
Q4 2015

REGN Guru Trades in Q4 2015

Pioneer Investments 391 sh (New)
Joel Greenblatt 4,157 sh (New)
Jim Simons 107,262 sh (New)
Ken Fisher 615 sh (+22.02%)
Ron Baron 7,463 sh (unchged)
Samuel Isaly 111,000 sh (unchged)
Ray Dalio Sold Out
Vanguard Health Care Fund 2,280,494 sh (-6.84%)
Frank Sands 3,698,553 sh (-10.62%)
Mario Gabelli 1,378 sh (-35.76%)
Paul Tudor Jones 700 sh (-35.78%)
» More
Q1 2016

REGN Guru Trades in Q1 2016

Steven Cohen 109,700 sh (New)
Ray Dalio 900 sh (New)
Jim Simons 216,962 sh (+102.27%)
Vanguard Health Care Fund 3,169,490 sh (+38.98%)
Samuel Isaly 137,000 sh (+23.42%)
Pioneer Investments Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 613 sh (-0.33%)
Mario Gabelli 1,343 sh (-2.54%)
Frank Sands 3,387,921 sh (-8.40%)
Ron Baron 5,011 sh (-32.86%)
Joel Greenblatt 2,525 sh (-39.26%)
» More
Q2 2016

REGN Guru Trades in Q2 2016

Paul Tudor Jones 2,956 sh (New)
Joel Greenblatt 30,151 sh (+1094.10%)
Vanguard Health Care Fund 3,279,190 sh (+3.46%)
Ken Fisher 613 sh (unchged)
Steven Cohen Sold Out
Ray Dalio Sold Out
Ron Baron 4,987 sh (-0.48%)
Mario Gabelli 1,329 sh (-1.04%)
Jim Simons 210,762 sh (-2.86%)
Frank Sands 2,659,741 sh (-21.49%)
Samuel Isaly 108,200 sh (-21.02%)
» More
» Details

Insider Trades

Latest Guru Trades with REGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CSLLY, NAS:ALXN, OTCPK:NVZMY, NAS:SHPG, NAS:VRTX, OTCPK:ALIOY, NAS:BIIB, NAS:INCY, NAS:BMRN, OTCPK:UCBJF, NAS:MDVN, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:ALNY, NAS:TSRO, NAS:UTHR, NAS:GRFS, NAS:ANAC » details
Traded in other countries:RGO.Germany, REGN.Mexico, REGN.Switzerland, 0R2M.UK,
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Regeneron Pharmaceuticals Inc was incorporated in in the State of New York on January 11, 1988. The Company is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The Company's preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. Its manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 490,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 74,000liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. Its competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current and potential future local, state, federal, and foreign regulations.

Guru Investment Theses on Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals - May 23, 2016

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Regeneron Pharmaceuticals Inc

Baron Funds Comments on Regeneron Pharmaceuticals Guru stock highlight
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) fell in the first quarter as a result of the significant sell-off in the biotech/pharma space and a miss on the top and bottom lines versus the expected fourth quarter results. 2016 guidance for Eylea (its lead ophthalmology asset) was sharply down from 2015. Launch of its new cardiovascular drug, Praluent, has been slow, and it lost a court case involving the drug. We have trimmed our position but decided that Regeneron deserved benefit of the doubt. Given Sanofi’s 22% ownership and its reliance on company for R&D productivity, we believe Regeneron enjoys a privileged position in the biotech universe. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 63.87
REGN's P/E(ttm) is ranked lower than
74% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 29.00 vs. REGN: 63.87 )
Ranked among companies with meaningful P/E(ttm) only.
REGN' s P/E(ttm) Range Over the Past 10 Years
Min: 22.84  Med: 80.84 Max: 169.6
Current: 63.87
22.84
169.6
Forward P/E 27.10
REGN's Forward P/E is ranked lower than
72% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 19.65 vs. REGN: 27.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 63.87
REGN's PE(NRI) is ranked lower than
73% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. REGN: 63.87 )
Ranked among companies with meaningful PE(NRI) only.
REGN' s PE(NRI) Range Over the Past 10 Years
Min: 22.84  Med: 80.84 Max: 169.6
Current: 63.87
22.84
169.6
Price/Owner Earnings (ttm) 58.78
REGN's Price/Owner Earnings (ttm) is ranked lower than
66% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 32.43 vs. REGN: 58.78 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
REGN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 49.67  Med: 108.94 Max: 1511.41
Current: 58.78
49.67
1511.41
P/B 10.34
REGN's P/B is ranked lower than
84% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. REGN: 10.34 )
Ranked among companies with meaningful P/B only.
REGN' s P/B Range Over the Past 10 Years
Min: 2.47  Med: 9.95 Max: 26.41
Current: 10.34
2.47
26.41
P/S 9.97
REGN's P/S is ranked higher than
55% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.19 vs. REGN: 9.97 )
Ranked among companies with meaningful P/S only.
REGN' s P/S Range Over the Past 10 Years
Min: 3.69  Med: 12.8 Max: 27.67
Current: 9.97
3.69
27.67
PFCF 44.37
REGN's PFCF is ranked lower than
69% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 28.22 vs. REGN: 44.37 )
Ranked among companies with meaningful PFCF only.
REGN' s PFCF Range Over the Past 10 Years
Min: 36.13  Med: 108.42 Max: 7496
Current: 44.37
36.13
7496
POCF 28.76
REGN's POCF is ranked lower than
59% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 23.11 vs. REGN: 28.76 )
Ranked among companies with meaningful POCF only.
REGN' s POCF Range Over the Past 10 Years
Min: 21.69  Med: 52.77 Max: 316.18
Current: 28.76
21.69
316.18
EV-to-EBIT 33.43
REGN's EV-to-EBIT is ranked lower than
63% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 23.97 vs. REGN: 33.43 )
Ranked among companies with meaningful EV-to-EBIT only.
REGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -108.7  Med: -6.1 Max: 1948.5
Current: 33.43
-108.7
1948.5
EV-to-EBITDA 31.09
REGN's EV-to-EBITDA is ranked lower than
64% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. REGN: 31.09 )
Ranked among companies with meaningful EV-to-EBITDA only.
REGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -141.9  Med: -7.1 Max: 387.4
Current: 31.09
-141.9
387.4
Shiller P/E 296.83
REGN's Shiller P/E is ranked lower than
95% of the 56 Companies
in the Global Biotechnology industry.

( Industry Median: 47.58 vs. REGN: 296.83 )
Ranked among companies with meaningful Shiller P/E only.
REGN' s Shiller P/E Range Over the Past 10 Years
Min: 251.47  Med: 1095.85 Max: 35046
Current: 296.83
251.47
35046
Current Ratio 3.37
REGN's Current Ratio is ranked lower than
59% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.35 vs. REGN: 3.37 )
Ranked among companies with meaningful Current Ratio only.
REGN' s Current Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.43 Max: 20.69
Current: 3.37
2.55
20.69
Quick Ratio 3.04
REGN's Quick Ratio is ranked lower than
60% of the 932 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. REGN: 3.04 )
Ranked among companies with meaningful Quick Ratio only.
REGN' s Quick Ratio Range Over the Past 10 Years
Min: 2.55  Med: 6.32 Max: 20.5
Current: 3.04
2.55
20.5
Days Inventory 222.24
REGN's Days Inventory is ranked lower than
73% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 131.23 vs. REGN: 222.24 )
Ranked among companies with meaningful Days Inventory only.
REGN' s Days Inventory Range Over the Past 10 Years
Min: 65.06  Med: 124.08 Max: 780.78
Current: 222.24
65.06
780.78
Days Sales Outstanding 137.55
REGN's Days Sales Outstanding is ranked lower than
84% of the 588 Companies
in the Global Biotechnology industry.

( Industry Median: 62.24 vs. REGN: 137.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
REGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 23.13  Med: 64.12 Max: 157.07
Current: 137.55
23.13
157.07
Days Payable 92.66
REGN's Days Payable is ranked higher than
65% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 54.96 vs. REGN: 92.66 )
Ranked among companies with meaningful Days Payable only.
REGN' s Days Payable Range Over the Past 10 Years
Min: 92.66  Med: 569.61 Max: 2718.58
Current: 92.66
92.66
2718.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
REGN's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 547 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. REGN: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
REGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.7  Med: -7 Max: -2.5
Current: -2.5
-14.7
-2.5

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 39.15
REGN's Price/Net Current Asset Value is ranked lower than
93% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. REGN: 39.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
REGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.34  Med: 10.47 Max: 157.38
Current: 39.15
3.34
157.38
Price/Tangible Book 10.38
REGN's Price/Tangible Book is ranked lower than
77% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 4.78 vs. REGN: 10.38 )
Ranked among companies with meaningful Price/Tangible Book only.
REGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.54  Med: 5.59 Max: 22
Current: 10.38
1.54
22
Price/Projected FCF 6.82
REGN's Price/Projected FCF is ranked lower than
69% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.64 vs. REGN: 6.82 )
Ranked among companies with meaningful Price/Projected FCF only.
REGN' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.92  Med: 17.21 Max: 206.31
Current: 6.82
5.92
206.31
Price/Median PS Value 0.78
REGN's Price/Median PS Value is ranked higher than
66% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 1.01 vs. REGN: 0.78 )
Ranked among companies with meaningful Price/Median PS Value only.
REGN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 0.99 Max: 4.14
Current: 0.78
0.17
4.14
Price/Graham Number 5.43
REGN's Price/Graham Number is ranked lower than
78% of the 178 Companies
in the Global Biotechnology industry.

( Industry Median: 2.74 vs. REGN: 5.43 )
Ranked among companies with meaningful Price/Graham Number only.
REGN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.33  Med: 6.71 Max: 10.19
Current: 5.43
1.33
10.19
Earnings Yield (Greenblatt) (%) 2.97
REGN's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. REGN: 2.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
REGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 2.3 Max: 24.9
Current: 2.97
0.1
24.9

More Statistics

Revenue (TTM) (Mil) $4,649
EPS (TTM) $ 6.30
Beta1.40
Short Percentage of Float5.10%
52-Week Range $329.09 - 592.59
Shares Outstanding (Mil)105.29

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 5,095 6,143 7,204 8,048
EPS ($) 10.55 14.24 17.17 25.06
EPS w/o NRI ($) 10.55 14.24 17.17 25.06
EPS Growth Rate
(3Y to 5Y Estimate)
18.12%
Dividends Per Share ($)
» More Articles for REGN

Headlines

Articles On GuruFocus.com
3 of Frank Sands' Top 5 Transactions in 2nd Quarter Were Reductions Aug 14 2016 
Edward Owens Top 2nd Quarter Investments Aug 03 2016 
Frank Sands Sells Visa, Baidu, Alibaba May 24 2016 
Baron Funds Comments on Regeneron Pharmaceuticals May 23 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 
Weekly CFO Sells Highlights: Facebook, Fitbit, Regeneron Pharmaceuticals Nov 23 2015 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Weekly CFO Sells Highlight: Acadia Healthcare, Facebook, Regeneron Pharmaceuticals Aug 24 2015 

More From Other Websites
[$$] Regeneron Bulls Should Keep Eye on the Prize Sep 30 2016
Regeneron Pharmaceuticals Falls As Combo Therapy Worse Than Eylea Alone Sep 30 2016
What Will Gilead Try Buying Next? Polls Offer Some 'Incyte' Sep 30 2016
What Do Analysts Say about Regeneron’s Upside Potential? Sep 30 2016
Why RBS, Cheniere Energy, Regeneron Pharmaceuticals & Two Other Stocks Are in Spotlight Today Sep 30 2016
Regeneron Is a Late Entrant in Immuno-Oncology Space Sep 30 2016
Regeneron's Eylea combination therapy fails mid-stage study Sep 30 2016
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta)... Sep 30 2016
7:01 am Regeneron Pharma announces the phase 2 study of aflibercept co-formulated with rinucumab... Sep 30 2016
Regeneron Announces Phase 2 Study of Aflibercept Co-Formulated with Rinucumab (anti-PDGFR-beta)... Sep 30 2016
Amgen, Biogen, Gilead Could Spike VA Pricing To Skirt California Measure Sep 29 2016
Why Teva and Regeneron Entered Collaboration Agreement Sep 29 2016
How Regeneron Is Working to Maintain Eylea’s Dominance Sep 29 2016
How Does Regeneron’s 2016 Guidance Look? Sep 29 2016
What’s the Word on Street for Vertex? Sep 28 2016
Goldman Sachs: Pharma Stocks That Need Price Hikes to Thrive Better Find a New Strategy Fast Sep 27 2016
The Drug Price Increase Debate: Separating The Winners From The Losers Sep 27 2016
Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US :... Sep 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)